High‐performance liquid chromatography with solid‐phase extraction for the quantitative determination of nilotinib in human plasma
Authors:
- 10 November 2009
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 24 (7) , 789-793
Abstract
A simple, rapid and sensitive high‐performance liquid chromatography (HPLC)‐based method with ultraviolet detection was developed for the quantitation of nilotinib, a tyrosine kinase inhibitor, in human plasma. Nilotinib and the internal standard dasatinib were separated using a mobile phase of 0.5% KH2PO4 (pH2.5)–acetonitrile–methanol (55:25:20, v/v/v) on a Capcell Pak MG II column (250 × 4.6 mm) at a flow rate of 0.5 mL/min and optical measurement at 250 nm. Analysis required only 100 μL of plasma and involved a rapid and simple solid‐phase extraction with an Oasis HLB cartridge, which gave recoveries from 72 to 78% for nilotinib and from 74 to 76% for dasatinib. The lower limit of quantification for nilotinib was 10 ng/mL. The linear range of this assay was between 10 and 5000 ng/mL (r2 > 0.9992 for the regression line). Intra‐ and inter‐day coefficients of variation were less than 10.0% and accuracies were within 10.4% over the linear range. Our results indicate that this method is applicable to the monitoring of plasma levels of nilotinib in a clinical setting. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometryJournal of Chromatography B, 2009
- New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasmaJournal of Chromatography B, 2009
- Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaClinical Therapeutics, 2008
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood, 2008
- High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparationsJournal of Chromatography B, 2007
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood, 2006
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Bioanalytical Method Validation—A Revisit with a Decade of ProgressPharmaceutical Research, 2000